Skip to main content
. 2017 Oct 14;23(38):7025–7036. doi: 10.3748/wjg.v23.i38.7025

Table 5.

Postoperative pathology n (%)

Variable Total, n = 1000 First 10 yr, 1993-2002 Second 10 yr, 2003-2012 Last 5 yr, 2013-2017
Site of the tumor
Ampullary tumor 312 (31.2) 92 (30.7) 145 (32.8) 75 (29)
Pancreatic head mass 556 (55.6) 171 (57) 257 (58.1) 128 (49.6) 0.0001
CBD duct tumor 41 (4.1) 16 (5.3) 13 (2.9) 12 (4.7)
Duodenal tumor 61 (6.1) 20 (6.7) 27 (6.1) 14 (5.4)
Uncinate process mass 30 (3) 1 (0.3) 0 29 (11.3)
Pathological diagnosis
Adenocarcinoma 836 (83.6) 250 (83.3) 357 (80.7) 229 (88.8)
Undifferentiated carcinoma 20 (2) 1 (1.7) 19 (4.3) 0
Papillary cystadenocarcinoma 6 (0.6) 4 (1.3) 2 (0.5) 0 0.0001
Lymphoma 4 (0.4) 2 (0.6) 2 (0.5) 0
Neuroendocrine tumor 28 (2.8) 12 (4) 10 (2.3) 6 (2.3)
Solid pseudopapillary tumor 20 (2) 5 (1.7) 8 (1.8) 7 (2.7)
Chronic pancreatitis 24 (2.4) 6 (2) 14 (3.2) 4 (1.6)
Benign cyst 12 (1.2) 3 (1) 8 (1.8) 1 (0.4)
Adenoma with dysplasia 41 (4.1) 15 (5) 19 (4.3) 7 (2.7)
Gastrointestinal stromal tumor 2 (0.2) 0 1 (0.2) 1 (0.4)
Glomus 1 (0.1) 1 (0.3) 0 0
Adenosquamous 2 (0.2) 1 (0.3) 1 (0.2) 0
Pleomorphic adenoma 1 (0.1) 0 1(0.2) 0
Adenomyoma 3 (0.3) 0 0 3 (1.2)
Malignant 870 (87) 258 (86) 382 (86.4) 230 (89.1) 0.38
Borderline 48 (4.8) 17(5.7) 18 (4.1) 13 (5.1)
benign 82 (8.2) 25 (8.3) 42 (9.5) 15 (5.8)
Number of dissected lymph node 6 (0-40) 5 (0-18) 6 (0-40) 6 (0-40) 0.59
Number of lymph node infiltration 0 (0-14) 0 (0-3) 0 (0-14) 0 (0-14) 0.07
Perineural infiltration 187 (18.7) 62 (20.7) 75 (17) 50 (19.9) 0.09
Perivascular infiltration 134 (134) 40 (13.3) 66 (14.9) 28 (10.9) 0.13
Pancreatic safety margin
R1 91 (9.1) 40 (13.3) 41 (9.3) 10 (3.8) 0.01
R2 15 (1.5) 7 (2.3) 6 (1.4) 2 (0.7)